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Background: Developments in enzyme replacement therapy have kindled discussions on adding Pompe disease,
characterized by progressive muscle weakness and wasting, to neonatal screening. Pompe disease does not fit
traditional screening criteria as it is a broad-spectrum phenotype disorder that may occur in lethal form in early infancy
or manifest in less severe forms from infancy to late adulthood. Current screening tests cannot differentiate between
these forms. Normally, expanding screening is discussed among experts in advisory bodies. While advisory reports
usually mention the procedures and outcome of deliberations, little is known of the importance attached to different
arguments and the actual weighing processes involved. In this research we aim to explore the views of a wide range
of relevant professionals to gain more insight into the process of weighing pros and cons of neonatal screening for
Pompe disease, as an example of the dilemmas involved in screening for broad-spectrum phenotype disorders.
Methods: We conducted 24 semi-structured interviews with medical, lab, insurance and screening professionals, and
executive staff of patient organisations. They were asked about their first reaction to neonatal screening for Pompe
disease, after which benefits and harms and requirements for screening were explored in more detail.
Results: Advantages included health gain by timely intervention, avoiding a diagnostic quest, having a reproductive
choice and gaining more knowledge about the natural course and treatment. Being prepared was mentioned as an
advantage for the later manifesting cases. Disadvantages included treatment costs and uncertainties about its effect,
the timing of treatment in later manifesting cases, the psychological burden for the patient-in-waiting and the family.
Also the downsides of having prior knowledge as well as having to consider a reproductive option were mentioned
as disadvantages.
Conclusion: When weighing pros and cons, interviewees attach different importance to different arguments, based on
personal and professional views. Professionals expect benefits from neonatal screening for Pompe disease, especially
for early-onset cases. Some interviewees valued screening in later manifesting cases as well, while stressing the need
for adequate support of pre-symptomatic patients and their families. Others considered the psychological burden and
uncertainties regarding treatment as reasons not to screen.Background
In neonatal screening early detection of serious childhood
disorders allows for interventions that can prevent or
postpone irreversible health damage in the infant. Over
the years, in many countries the number of disorders
screened for has expanded [1]. National arrangements
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pros and cons of a potential new screening [2]. These
criteria help to assess whether the expected benefits
surpass the potential harm of screening. For instance
the availability of a treatment to achieve health gain
from screening or intervention is essential when deciding
on the potential benefit of screening. While advisory
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different arguments and the actual weighing processes
involved.
In this research we aim to explore the views of a wide
range of relevant professionals to gain more insight into
the process of weighing pros and cons of neonatal
screening. We focus on the case of glycogen storage disease
type II, or Pompe disease, a severe autosomal recessive
lysosomal storage disorder [MIM ID #232300], involving
progressive muscle weakness and respiratory failure.
Developments in treatment via enzyme replacement
therapy (ERT) and tests have kindled discussions on adding
Pompe disease to neonatal screening. Some jurisdictions
have introduced pilot screening programmes for Pompe
disease. In Taiwan, screening started in 2005 [3], in Austria
a pilot has been conducted [4] and in the USA several
states have started screening [5]. Based on an evidence
report [6] in May 2013 the US Secretary’s Discretionary
Advisory Committee for Heritable Disorders in Newborns
and Children (DACHDNC) advised adding Pompe Disease
to the recommended uniform screening panel (RUSP)
for newborns (recommended to all states) [7], though, at
the time of writing, May 2014, the Secretary’s decision
is pending.
Pompe disease is particularly interesting as an example
of the dilemmas involved in screening for broad-spectrum
phenotype disorders. So far, with a few recent exceptions,
neonatal screening has been restricted to childhood-onset
disorders, where early detection and intervention or treat-
ment can prevent irreversible health damage [8]. Current
screening tests for Pompe disease not only detect the
classic infantile form - lethal in the first years of life,
when untreated – but also less severe cases, for which
the age of onset might vary from infancy to adulthood
[9]. Since the traditional focus of neonatal screening
does not fit well with the potential outcome of this new
kind of screening for broad-spectrum disorders, intro-
duction of neonatal screening for Pompe disease would
need to be carefully considered from all angles, and
screening criteria might need rethinking [10,11].
Recently, the inclusion of views of stakeholders and
members of the general public in policy deliberations has
been promoted [12,13]. This is expected to increase trans-
parency, accountability and quality of decision making,
since it brings in knowledge and views that would other-
wise be unheard. Elsewhere we have made a quantitative
comparison of patients’ and the general public’s views
on expanding neonatal screening for Pompe disease [14].
Here we explore the views of a wide range of relevant
professionals. We selected professionals that were either
knowledgeable on several aspects of Pompe disease, cover-
ing as much as possible the range of expertise involved
in the continuity of care for this disease, or were involved
in the organisation of screening or health care, includingexecutive staff of patient organisations. Given these
diverse experiences and kinds of expertise we expected
these professionals to be able to develop an informed
opinion on pros and cons of this potentially new type of
screening. Because of the need to explore arguments
we have chosen semi-structured interviews as a research
method.
In the Netherlands, since 2007 the national neonatal
screening programme has been expanded from 3 to 19
disorders based on discussions held in 2005 [15]. Pompe
disease was considered as a candidate for neonatal screen-
ing, but incorporation in the programme was declined
because of insufficient evidence of the effect of treatment
and uncertainties regarding the availability of treatment at
that time. It was stated though, that further developments
might merit reconsidering screening for Pompe disease
[15]. A study from 2003 reported that in the Netherlands
classic infantile cases of Pompe disease are diagnosed
at a median age of about 5 months [16] when severe,
irreversible muscle weakness has already occurred. Earlier
detection would allow for earlier treatment and better
health status in infants with this classic infantile form
of the disease [17]. However, through screening late
manifesting cases would also be detected. This would
create a group of pre-symptomatic patients, or patients-
in-waiting [18]. In the Netherlands patients with later
manifesting forms of Pompe disease are treated with
infusions once every two weeks starting when patients
show significant signs of muscle weakness or respiratory
failure. ERT is very costly, dosage depends on weight.
Costs per adult patient vary between roughly 400.000 and
700.000 Euro a year [19]. Currently the costs are covered
through basic health insurance. The Ministry of Health
has started price negotiations with the drug manufacturer
while also promoting more efficacious drug use through
various measures [20].
Objective
Given rapid developments in understanding etiology, test-
development, and treatment options for broad-phenotype
disorders such as Pompe disease, in this research we
explore the views of a wide range of relevant professionals
to gain more insight into the process of weighing pros and
cons and the importance attached to different arguments
in considering neonatal screening for Pompe disease. The
aim is to increase transparency and stimulate informed
policy-making in expanding neonatal screening, especially
of broad-phenotype disorders.
Methods
Sample
We selected 24 professionals (see 'List of professional
background of interviewees' below) who had experience
with various aspects of Pompe disease or had prior
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rologists, physiatrists, family doctors), and health care
policy officials who were knowledgeable about screening
(such as representatives from the Netherlands’ Centre
for Population Screening, the Health Care Insurance
Board, and a well-baby clinic doctor). Also executive
staff members of two patient organisations (respectively
dedicated to neuromuscular and metabolic diseases) who
have members with Pompe disease were included. We
selected this purposeful sample because we expected
these professionals to be capable of developing informed
opinions regarding the pros and cons and consequences
of screening for Pompe disease for patients, their family
members, health care and/or wider society. The experts
were selected through initial contacts at the national
Center for Lysosomal and Metabolic Diseases, at Erasmus
MC University Medical Center, that treats all Dutch
Pompe patients, and further suggestions via snowbal-
ling. Interviewees came from various regions in the
Netherlands and those working in academic medical
centers were employed by 4 of the total amount of 8 of
these centers.
List of professional background of interviewees
Medical professionals:
Neurologist (2)
Pediatrician (3)
General practitioner (2)
Physiotherapist (2)
Pulmonologist (1)
Clinical geneticist (1)
Physiatrist (2)
Midwife (1)
Well-baby clinic physician (1)
Other experts:
Neonatal screening organisation staff member (2)
National Institute for Public Health and the
Environment (RIVM) executive staff member (2)
Patient organisation executive staff member (2)
Health insurance official (1)
Clinical chemist (2)
Design
Between 2009 and 2011, we conducted 24 semi-structured
interviews based on a protocol developed on the basis of
our previous study of screening criteria in the Netherlands
[21], recent literature on expanding neonatal screening
and developments in research and treatment of Pompe
disease. The protocol was tested on 2 key experts and
made more structured. Prior to the interviews the
remaining 22 interviewees received concise writteninformation on Pompe disease, screening and treatment
(see Additional file 1). They were informed that currently
classic-infantile cases are diagnosed at a median age of
about 5 months. In addition, it was verbally explained that
in the Netherlands currently 180.000 infants have a heel
prick each year. In case of neonatal screening for Pompe
disease, 1-2 classic infantile cases, and 3–4 cases with
less severe forms were to be expected each year, and an
additional 80 false positive cases. Information was given on
current procedures in the Netherlands to start treatment
by biweekly infusions in later onset cases when patients
show significant signs of muscle weakness or decreased
pulmonary function. We did not provide a list of screen-
ing criteria, such as an overview of the Wilson and
Jungner criteria, that are often used to weigh pros and
cons. Rather we focused our questions on the potential
benefits and harms of screening in the specific case of
Pompe disease, thereby exploring the different conse-
quences of screening for classic infantile cases and the
later manifesting forms. After discussing their experiences
with Pompe patients or screening in general, interviewees
were asked about their first reaction to the idea of neo-
natal screening for Pompe disease, after which benefits
and harms for both classic infantile as well as less severe
later onset cases were discussed, and pros and cons were
weighed. When opportune, requirements for screening
were explored.
Data collection and analysis
The first interviews and some later interviews were con-
ducted by two researchers jointly (TR and CE), the other
interviews by one researcher (TR). The interviews were
tape-recorded and transcribed literally by a third party.
On the basis of the interview protocol a code list was de-
veloped (TR and CE): themes were identified and grouped
under headings related to ‘introduction’, ‘experiences’, ‘opin-
ions’, ‘advantages’, ‘disadvantages’, ‘prerequisites of screening’,
and ‘continuity of care’. The first interviews were coded
separately by two researchers (TR and CE), the codes were
compared and discussed in case of differences until agree-
ment was reached. Later interviews were coded by one
researcher (either TR or CE), and unclear sections were
discussed with the other researcher until agreement was
reached. During this process some codes were refined
or expanded.
Ethical approval
This study forms part of a larger project which was
approved by the institutional review boards of the
Erasmus MC University Medical Center (MEC2007-103,
addendum 3) and the VU University Medical Center (letter
2010/104). However, interviews with professionals on their
opinion regarding health care are considered exempt from
strict requirements for ethical approval.
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Relevant and recurrent themes are discussed below.
They fall under the following headings: first reaction,
benefits and harms for classic infantile and later man-
ifesting cases, weighing pros and cons and prerequi-
sites for screening. We have selected citations to
illustrate the views and arguments used within the
themes. The number of the interview is indicated be-
tween brackets.
First reaction
After the introduction, when asked about their first reac-
tion whether Pompe disease should be screened for neo-
natally several interviewees expressed their support,
while some are unsure, and others stated their reserva-
tions or objections about screening.
Yes, I am strongly in favour of that.
(#5 Medical professional)I have doubts.
(#8 Other expert)Then I would say, no.
(#12 Medical professional)
Benefits and harms of screening in case of classic
infantile cases
When asked for arguments for their opinion in terms of
benefits of screening for classic infantile cases, respon-
dents often mentioned shortening the diagnostic delay
and subsequent health gain.
The real gain, I think, are those children, those babies
(…) whom you discover right away, and whom you can
start treating right away.
(#4 Medical professional)
In some interviews having reproductive options for the
next pregnancy was discussed, and sometimes mentioned
as a benefit.
I think it would be a criminal act to burden one
family with 2 children with a severe muscular disorder
if we have the technology to prevent this. (…) I think
this is a big advantage, because then you can prevent
it happening again.
(#5 Medical professional)However, as some other interviewees remarked, since
the median age of onset in classic infantile cases has
been reported to be 5 months of age, already in the
current situation without neonatal screening parents of
classic infantile Pompe disease patients would have been
informed early enough to allow for reproductive options
for future pregnancies.
As for the drawbacks, respondents mentioned uncer-
tainty about the evidence and long-term effects of early
treatment. It was known at the time that not all patients
responded equally well to treatment, and that some
patients experienced allergic reactions. For some this would
be a reason not to screen, while others considered this as
something that should be kept in mind while screening.
…what is happening is really very spectacular (…), but I
myself am not yet convinced of the end result, that the
end result will be good enough to warrant screening.
(#7 Other expert)
You cannot predict per person, much more research
needs to be done on that, but you see there are
children who are doing very well, children who
are doing well and there are children who are
doing well and then have an enormous dip, get
pneumonia, start mechanical ventilation and
become rather physically handicapped at age three or
four. (…) For the adults we see that the majority still
responds well. There are differences there too, some
can stand and walk again and do not need (…) a
cane any more, others can walk, and another one
still has problems. And rarely an individual has an
allergic reaction.
(#20 Other expert)
A respondent remarked that new, treatment-independent
symptoms were seen that were not known before because
previously, patients died at an early age. It was stated that it
is a disadvantage that in fact this part of the ‘natural history’
of the disorder is not completely known yet.
…patients that are treated are developing symptoms
that we did not know existed in relation to Pompe
disease and they will not be treatment-dependent, they
belong to the whole spectrum… but … they died and
so you did not see these problems, hearing problems,
for instance.
(#6 Medical professional)
Also costs were mentioned as a drawback, and were
often seen as something to be resolved by parties such
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society at large. Some interviewees expected prices of
treatment to drop in the future.
Benefits and harms of screening in later manifesting, less
severe, cases
Some respondents expected clear benefit from early
detection through screening for the less severe cases.
The ability to monitor and avoid a diagnostic odyssey
should health problems develop was seen as an important
advantage.
Another advantage is that you could start treatment
in late onset patients in a timely manner.(…) They
always become ill. And when those patients fall ill,
they often have been ailing for 5 to 10 years. And I
think it is unethical – if you can diagnose - to think I
will wait until health complaints develop.
(#5 Medical professional)
For parents knowing what might be the matter with
their child in case of health problems and knowing what
to expect was mentioned as an advantage.
And therefore that is a big advantage of such a screening,
that parents have some more clarity, on what is the
matter with their child. And when I argue this way, we
just took myself as an example, I would not want to
know, but I would want to know in case of my child.
(#22 Medical professional)
It was however also mentioned as a drawback that in
case of Pompe disease a precise prediction of the disease
development cannot be given.
One interviewee saw the possibility to start physiotherapy
by means of prevention as an advantage, though it was
clear that more research was needed to find out what
exercise programmes would work best.
…if I speak from my professional field I think you can
start with exercises for specific muscle groups, so you
can …prevent potential muscle damage.
(#11 Medical professional)
Others were more sceptical about the effects of
physiotherapy.
Another advantage did not relate to the individual
patient but to research. By monitoring ‘patients-in-waiting’
after a positive screening more knowledge can be obtained
about the development of the disorder but also about
administering ERT treatment.I also hope that in the future it will become more
clear… what … schedule for administering (treatment
CE)… has the most effect. Probably much can be
gained there as well.
(#14 Medical professional)
Being prepared was also seen as an advantage. People
might be able to anticipate future decisions regarding
education, sports or employment.
Choice of profession (is) of course also of paramount
importance. Because if you know this (the disease CE)
is coming, then you can say: I should certainly not
become a gardener.
(#20 Other expert)
However, having prior knowledge was sometimes men-
tioned as a disadvantage as well.
I think for very many people, the majority, it is an
advantage that you can organise your life in relation
to what will happen in the future. But of course that
has disadvantages. Indeed if you look at education,
employment and such, that you do not know when
something is going to happen and that you already do
make choices, maybe make the wrong choices. Or do
not make a choice you prefer more. (…)
(#22 Medical professional)
A disadvantage could be (…) I do not enter into this
relationship or I would like to have children but I
won’t because I know I will deteriorate in the future.
(#22 Medical professional)
Furthermore, many interviewees stated that the fact
the screening would not differentiate between classic in-
fantile cases and later manifesting, less severe forms of
Pompe disease was a serious drawback because of the
psychological burden this would bring to the patient and
his or her family.
And there is nothing you can…? No, then I would not
want to screen. Then I would not want to know. It is an
enormous burden (…) You have your child, you are
happy… and then you get the verdict (…) But we cannot
do something about it yet, only when your child becomes
hypotonic, then we can start acting. And then I wonder
whether that is of any use.
(#23 Medical professional)
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of his or her future health status.
…do you have to put this burden on the parents…and
the question whether they should tell their children
and in what phase they should tell them?
(#14 Medical professional)
For parents of patients with a potentially late disease
manifestation having reproductive options in future preg-
nancies was also seen by some as a drawback. Especially
since the age of onset and severity of symptoms are largely
unpredictable in such cases. However, some interviewees
saw having a reproductive choice as an advantage in these
cases as well.
From a policy perspective, concerns were raised about
the robustness of the neonatal screening programme in
case screening for Pompe disease would be added.
…you should see how it would relate to the current
package. In some way it has to be uniform…to enable
clear information and to make sure participants can
make a good choice…. But that would imply they need
some knowledge: what disorders do I screen, what does
it mean, what are potential consequences? And, of
course, with Pompe disease that is a difficult story to
tell, so that is something you should really look into, if
that story can be told well.
(#15 Other expert)
Other questions and concerns were raised in rela-
tion to pre-symptomatic patients and difficulties with
obtaining health care insurance, life insurance and
employment.Weighing pros and cons
After asking for a first reaction and exploring benefits and
disadvantages of screening, respondents were invited to
weigh pros and cons. Several interviewees thought the
benefit for classic infantile cases was more important than
the burden for later onset cases
I am afraid that if I must weigh…that the early
infantile (cases) have so much benefit, the gain is so
big that if we reach them in time, that unfortunately it
is worth the burden.
(#3 Medical professional)
However, some respondents voiced a clear vote against
screening when weighing pros and cons.…you create many more problems than you solve if
you do it without being able to differentiate between
serious forms that need immediate treatment (and)
forms that will develop complaints only in 40 years…..I
think you will encounter opposition on many fronts,
and definitely morally-societally so to speak, if you
have (…) a lot of people whose parents have been told:
yes your child has Pompe disease, but we do not know
yet if health problems will develop in 10, 15 or 40
years…..
(#17 Other expert)
While a few respondents were critical towards neonatal
screening for Pompe disease throughout the interview
and opted against screening when weighing pros and
cons, some others were positive throughout the inter-
view towards neonatal screening and opted in favour of
screening. However, a few interviewees initially were
positive and changed their opinion into a negative stance
towards screening during the interview, after having
considered the advantages and disadvantages in more
detail. This change of attitude seems mostly related to
the fact that the screening test would not be able to dif-
ferentiate between classic infantile cases and less severe
cases of Pompe disease manifesting at unknown age. The
interviewees felt that the burden of living in uncertainty
about the age of onset of a life threatening disease would
be too high.
Prerequisites
Supporters of screening as well as those who had doubts
about or objections to screening formulated prerequi-
sites for screening that were often directly related to
overcoming the perceived drawbacks. More evidence on
the effect of treatment was desired, though screening
was sometimes mentioned as a means to obtain more
evidence, for instance via a pilot. A test that would be able
to differentiate between classic infantile Pompe disease
and less severe forms was found desirable and for some
would be required before screening could be considered.
In the mean time it was suggested that research might
focus on alternatives for screening that would allow for an
earlier diagnosis and rapid transfer to specialized care after
symptoms would be detected by well-baby clinics or
family doctors.
Other requirements that were mentioned were that
the test characteristics needed to be optimised in order
to reduce the expected number of 80 false positives. The
amount of time needed between a positive test result and
a second test to confirm or exclude Pompe disease should
be as short as possible, according to the interviewees.
Parents who would receive a positive result were said
to need adequate support, not only immediately after
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with the implications. With regard to diagnosed patients-
in-waiting some interviewees argued that psychological
support should also be available.
Other considerations concerned potential discrimination
against pre-symptomatic Pompe patients in health and life
insurance, issues that need to be addressed before screening
could be implemented.
Given the sensitive character of the screening both in
terms of ethical considerations and cost, some mentioned
a wider societal debate would be relevant. It was also
mentioned that industry was interested in neonatal
screening, and therefore an independent process of
policy making should be safeguarded.
The practicalities of the screening process were also
discussed. It was mentioned that the midwives who give
the information in the last trimester of pregnancy on the
heel prick programme, as well as the screeners who in
many cases actually perform the heel prick need to be
able to explain the complicated outcomes of the screening.
The potential outcome of a ‘pre-symptomatic patient’ is
perceived as difficult to explain by professionals and
difficult to understand for parents, as it falls outside the
scope of the current screening programme. This issue
merits special attention before implementation, and better
education of screening professionals could therefore also
be considered as a prerequisite for screening.
Discussion
In the interviews we conducted with professionals from
various backgrounds in health care and neonatal screening
programs as well as patient organisation executive staff
members we were able to explore and discuss a range
of advantages and disadvantages of and prerequisites
for neonatal screening for Pompe disease. Advantages
for both classic infantile and later manifesting cases
included health gain, avoiding a diagnostic quest, having a
reproductive choice in future pregnancies, and the ability
to gain more knowledge about the disease and treatment.
Being prepared was mentioned as an advantage for the
later manifesting cases. Disadvantages for both ends of the
spectrum included costs and uncertainties about the effect
of treatment. In later manifesting cases most notably the
timing of treatment and the psychological burden for the
patient-in-waiting and the family were seen as major
drawbacks. Also the downsides of having a reproductive
option were mentioned. Ideally a test should yield only
limited false positive and false negative cases and be able
to differentiate between the different forms of Pompe
disease. However, for some interviewees the lack of
discriminative power was not a reason not to screen.
Other requirements included proper information and
support for parents, education for health care professionals
and screeners.We also gained insight into the process of weighing
pros and cons. Individuals draw different conclusions
during this process. Some would opt for screening since
for them the benefit for classic infantile cases outweighs
the potential burden for patients with a late disease
manifestation. Others would decline screening because
they are of the opposite opinion, or for them there
would be too many uncertainties as to the evidence and
onset of treatment.
Strength and limitations
A strength of this study is the fact that we were able to
interview a broad range of professionals and executive
staff of patient organizations knowledgeable on screening
and/or health care for Pompe disease patients. A weakness
is that interviewees differed in the amount of detailed
knowledge about the latest published and unpublished
evidence on efficacy and failures of enzyme therapy.
Though most of them were knowledgeable about Pompe
disease and its treatment, we cannot be sure whether
that has affected the outcome. It should be noted that
more evidence on the effect of treatment via enzyme
replacement therapy was published after most of the
interviews were conducted [22], and the lack of evidence
at that time may have led to a cautious (or optimistic)
stance. However, uncertainties regarding cases in which
treatment is not effective remain and long-term follow
up would be necessary to answer questions concerning
the right time to start treatment in later manifesting,
slowly progressive cases and the effects of early treatment
in classic infantile cases.
As we purposely did not provide a list of screening cri-
teria in advance, not all criteria received similar attention.
For instance, while the availability of an effective treatment
was discussed in detail, the acceptability of treatment hardly
surfaced. We do not think this is because of an unfamiliar-
ity with the burden of the bi-weekly infusions. Further
research is needed to better understand the relevance
of this criterion on weighing pros and cons.
In this qualitative research we did not attempt to relate
the opinion on whether to screen or not to a particular
professional background. This possibility would, however,
be interesting to study further, given the fact that some
professional groups traditionally have been more involved
with neonatal screening policy, and their arguments and
opinions would perhaps be more influential than those of
other professional groups. In our sample, interestingly,
opinions sometimes varied within one specific subset of
interviewees. For instance, the executive staff member of
one patient organisation was in favour of screening,
whereas the executive staff member of another patient
organisation had serious objections to screening. This
might support earlier findings of diverging views on
neonatal screening among (parents) of Pompe disease
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processes that would occur in an actual advisory com-
mittee. Then all members would be presented with the
same evidence, and furthermore they would be able to
discuss and influence each other’s opinions. However, in
the case of Pompe disease not only evidence, but also ideas
about the ethical and social ramifications of screening play
an important role, as we will argue below.
Screening in children’s best interest
Traditionally the diseases incorporated in the neonatal
screening program are disorders for which early detection
can lead to prompt intervention or treatment in order to
prevent irreversible health damage to the infant. In the
case of screening for Pompe disease, however, the focus
on childhood disorders would be loosened as Pompe
disease is a broad-phenotype disorder and symptoms
may present at any age, including in adulthood.
In the case of neonatal screening for Pompe disease it
might be argued that not only the classic infantile cases,
but also those that fall ill in (early) childhood may benefit
from screening. Neonatal screening for Pompe disease
would, however, violate the autonomy of older minors and
future adults to decide for themselves whether they would
want information on their risk of developing Pompe
disease at an unpredictable age. In genetic testing for
adults, autonomy of choice is a key principle; people
must decide for themselves whether they want to know
their genetic make-up or predisposition for disease.
Autonomy of choice also holds for screening as an
instrument of public health, even though screening is
offered in the best interest of the population and a
high uptake may be strived for. In case of genetic testing
in minors European standards indicate a minor should
have reached a certain age to be able to make an informed
decision on having a test him-or herself [23]. For instance
in case of a disorder that is manifest in a family and that
may cause health problems already in the teenage years
timely testing is relevant. As for younger ages, testing
should only be considered if there is a clear benefit for the
child, for instance to prevent imminent health damage or
obtain a diagnosis in case of serious health problems.
Personal preferences
In our interviews professionals differed in their opinion
especially regarding detecting the later onset cases, but
also on the potential outcome of early treatment in classic
infantile cases. It is not self-evident that neonatal screen-
ing for Pompe disease would be in the best interest of
the child, let alone the future adult, though benefit can
certainly not be precluded. The case of Pompe disease
questions the format of neonatal screening as an instru-
ment of public health which would be in the best interest
of all and for which a high uptake should be achieved.Rather, it could be argued that personal preferences play a
major role in weighing pros and cons. The interviewees
from our study sometimes referred to their personal
(besides their professional) experiences and preferences.
It can be argued that in straightforward cases where
screening would entail direct benefit for the infant,
public-health authorities can more readily decide to
offer screening and strive for a high uptake. In more
complex cases, such as broad-phenotype disorders, the
question arises whether people shouldn’t be able to
decide for themselves whether they want to participate
in neonatal screening for such a disorder. This may be
dependent on their view of what is in the best interest
of their child and on whether they think they can cope
with or profit from potentially receiving information
that their child might fall ill at some point in time.
Options in a screening package
The possibility to offer options in the neonatal screening
package is not new. In recent years technical and policy
developments have led to the inclusion of disorders and
outcomes in screening packages around the world that
do not neatly fit the original intentions of neonatal
screening, for instance the disclosure of information on
carrier status. In the Netherlands, sickle cell disease
(SCD) was added to the neonatal screening programme
during a recent expansion in 2007. The screening test
for SCD also detected healthy carriers, and the detection
of carrier status was regarded as an unsolicited finding.
Though disclosing carrier status information would not
be of direct benefit for the infant, and could in fact be
regarded as a violation of the infant’s right not to know
and autonomy of choice, for the parents knowing the
carrier status of their infant could have benefits in view
of future reproductive options. Parents were therefore
given the option to opt out of receiving carrier status
information by ticking a box on the heel-prick card.
Since screening for cystic fibrosis has been added to the
Dutch programme in 2011, parents can choose whether
they want to receive their infant’s carrier status informa-
tion for that disorder, if detected, as well. The format for
stating preferences for both disorders was changed at
the same time: a box needs to be ticked to indicate
whether parents want or do not want to receive carrier
status information.
In a recent US article discussing newborn screening for
lysosomal storage disorders including Pompe disease it
was also argued to give parents an option [24]. However,
here the option for screening was suggested to be sub-
sumed under the heading of a research project, where
the protocol should be approved by an institutional
review board. Though it was perceived screening may
have advantages, a lack of evidence on most notably the
natural history and treatment were mentioned as
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fact research. The article suggests parents should be in-
formed about the shortcomings at the moment, so they
can decide for themselves whether they feel screening
would be in the best interest of their child. We would
like to add to that suggestion that research is also
needed to study the potential psychological burden of
disclosure of information and the best ways to support
parents and patients-in-waiting.
The possibilities to give parents an option in the
Netherlands may be partly different than the one
proposed for the US. In the US neonatal screening is
routine and mandated in many states, which may explain
the choice to subsume screening under the heading of
research. In the Dutch context, neonatal screening is
not mandatory, though almost 99% of the newborns are
screened each year. Since parents can opt in and opt
out of receiving information on the carrier status of
their child, in principle also other options could be added.
However, until now declining screening was only possible
for the complete package and not for individual disorders
or a subset of disorders. Perhaps Pompe disease could be
considered as a separate category, in which case other
disorders could be added for which evidence exists about
the advantages of screening, yet personal considerations
also play a role. When offering such an additional package
it would certainly be a challenge to inform parents ad-
equately about the possibilities of the program while safe-
guarding the uptake of screening for the core diseases for
which screening clearly provides a benefit for the infant.
Policy
In the coming years policy decisions have to be made on
whether neonatal screening for Pompe disease should be
made available and in what way. We hope the results
from the interviews can contribute to making informed
and transparent policy decisions. In making the arguments
for or against screening for this kind of broad-spectrum
phenotype disorders visible, a wider audience can start to
reflect on what benefits and harms may be involved. A
public discussion will improve people’s understanding and
enable exchange of views. Parents can profit from such a
discussion and reflect on what may be the benefit or harm
in their particular situation, so they may make a better
informed decision in case neonatal screening for Pompe
would be added to the programme.
Conclusions
In case of screening for Pompe disease, according to
professionals, advantages for both classic infantile and
later manifesting, less severe, cases included health gain,
avoiding a diagnostic quest, having a reproductive choice
in future pregnancies, and the ability to gain more know-
ledge about the disease and treatment. Being preparedwas mentioned as an advantage for the later manifesting
cases. Disadvantages for both forms included costs and
uncertainties about the effect of treatment. In later mani-
festing cases most notably the timing of treatment and
the psychological burden for the patient-in-waiting and
the family were seen as major drawbacks. Facing a repro-
ductive option was sometimes also mentioned as drawback.
Requirements for screening included proper information
and support for parents, education for health care profes-
sionals and screeners. Ideally a test should yield only limited
false positive and false negative cases and be able to
differentiate between the different forms of Pompe
disease. However, for some interviewees the lack of
discriminative power was not a reason not to screen.
Professionals draw different conclusions when weighing
pros and cons. Some would opt for screening since for
them the benefit for classic infantile cases outweighs the
potential burden for patients with a late disease manifest-
ation. Others would decline screening because they are
of the opposite opinion, or for them there would be too
many uncertainties as to the evidence and onset of treat-
ment. Personal preferences and views on the ethical and
social ramifications play an important role in considering
screening for this broad-phenotype condition, where
screening is not necessarily perceived to be in the best
interest of all.
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